Instituto Rosenbusch S.A. (ROSE) - Net Assets
Based on the latest financial reports, Instituto Rosenbusch S.A. (ROSE) has net assets worth AR$-526.19 Million ARS (≈ $-380.75K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AR$7.75 Billion ≈ $5.60 Million USD) and total liabilities (AR$8.27 Billion ≈ $5.99 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore Instituto Rosenbusch S.A. (ROSE) cash flow conversion to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AR$-526.19 Million |
| % of Total Assets | -6.79% |
| Annual Growth Rate | N/A |
| 5-Year Change | -364.17% |
| 10-Year Change | -732.17% |
| Growth Volatility | 203.92 |
Instituto Rosenbusch S.A. - Net Assets Trend (2000–2025)
This chart illustrates how Instituto Rosenbusch S.A.'s net assets have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Instituto Rosenbusch S.A. to see how much of total assets are deployed in long-term investments.
Annual Net Assets for Instituto Rosenbusch S.A. (2000–2025)
The table below shows the annual net assets of Instituto Rosenbusch S.A. from 2000 to 2025. For live valuation and market cap data, see ROSE stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | AR$-526.19 Million ≈ $-380.75K |
-113.19% |
| 2024-12-31 | AR$3.99 Billion ≈ $2.89 Million |
-12.26% |
| 2023-12-31 | AR$4.55 Billion ≈ $3.29 Million |
+1035.45% |
| 2022-12-31 | AR$400.51 Million ≈ $289.81K |
+101.07% |
| 2021-12-31 | AR$199.19 Million ≈ $144.13K |
+34.87% |
| 2020-12-31 | AR$147.69 Million ≈ $106.87K |
+27.86% |
| 2019-12-31 | AR$115.52 Million ≈ $83.59K |
-20.85% |
| 2018-12-31 | AR$145.95 Million ≈ $105.61K |
+68.58% |
| 2017-12-31 | AR$86.58 Million ≈ $62.65K |
+4.01% |
| 2016-12-31 | AR$83.24 Million ≈ $60.23K |
+17.86% |
| 2015-12-31 | AR$70.62 Million ≈ $51.10K |
+3.48% |
| 2014-12-31 | AR$68.24 Million ≈ $49.38K |
+18.37% |
| 2013-12-31 | AR$57.65 Million ≈ $41.72K |
-12.49% |
| 2012-12-31 | AR$65.88 Million ≈ $47.67K |
+17.13% |
| 2011-12-31 | AR$56.25 Million ≈ $40.70K |
+12.05% |
| 2010-12-31 | AR$50.20 Million ≈ $36.32K |
+6.93% |
| 2009-12-31 | AR$46.95 Million ≈ $33.97K |
+2.85% |
| 2008-12-31 | AR$45.65 Million ≈ $33.03K |
+21.73% |
| 2007-12-31 | AR$37.50 Million ≈ $27.13K |
+4.25% |
| 2006-12-31 | AR$35.97 Million ≈ $26.03K |
+5.37% |
| 2005-12-31 | AR$34.13 Million ≈ $24.70K |
+12.26% |
| 2004-12-31 | AR$30.41 Million ≈ $22.00K |
+7.58% |
| 2003-12-31 | AR$28.27 Million ≈ $20.45K |
+16.96% |
| 2002-12-31 | AR$24.17 Million ≈ $17.49K |
+91.96% |
| 2001-12-31 | AR$12.59 Million ≈ $9.11K |
+5.80% |
| 2000-12-31 | AR$11.90 Million ≈ $8.61K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Instituto Rosenbusch S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 297534.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | AR$8.09 Billion | % |
| Total Equity | AR$-800.17 Million | 100.00% |
Instituto Rosenbusch S.A. Competitors by Market Cap
The table below lists competitors of Instituto Rosenbusch S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mantle Minerals Ltd
AU:MTL
|
$5.12 Million |
|
TIMES CHINA HLDGS HD -10
F:T2H
|
$5.12 Million |
|
Mint Corp
V:MIT
|
$5.12 Million |
|
Maple Peak Investments Inc
V:MAP
|
$5.12 Million |
|
China Natural Resources Inc
NASDAQ:CHNR
|
$5.11 Million |
|
Golden Goliath Resources Ltd.
V:GNG
|
$5.11 Million |
|
Manchester and London Investment Trust plc
LSE:MNL
|
$5.11 Million |
|
PMPG Polskie Media S.A.
WAR:PGM
|
$5.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Instituto Rosenbusch S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,739,171,982 to -800,168,048, a change of -4,539,340,030 (-121.4%).
- Net loss of 4,597,736,040 reduced equity.
- Other factors increased equity by 58,396,010.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AR$-4.60 Billion | -574.6% |
| Other Changes | AR$58.40 Million | +7.3% |
| Total Change | AR$- | -121.40% |
Book Value vs Market Value Analysis
This analysis compares Instituto Rosenbusch S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | AR$1.81 | AR$166.00 | x |
| 2018-12-31 | AR$3.00 | AR$166.00 | x |
| 2019-12-31 | AR$2.46 | AR$166.00 | x |
| 2020-12-31 | AR$3.06 | AR$166.00 | x |
| 2021-12-31 | AR$4.16 | AR$166.00 | x |
| 2022-12-31 | AR$8.52 | AR$166.00 | x |
| 2023-12-31 | AR$97.89 | AR$166.00 | x |
| 2024-12-31 | AR$87.80 | AR$166.00 | x |
| 2025-12-31 | AR$-18.79 | AR$166.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Instituto Rosenbusch S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -71.80%
- • Asset Turnover: 0.83x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-0.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 8.43% | 12.27% | 0.56x | 1.24x | AR$-186.90K |
| 2001 | 4.87% | 6.96% | 0.57x | 1.22x | AR$-645.90K |
| 2003 | 12.52% | 11.66% | 0.85x | 1.26x | AR$713.50K |
| 2004 | 8.30% | 5.79% | 1.11x | 1.29x | AR$-516.80K |
| 2005 | 12.18% | 7.66% | 1.19x | 1.33x | AR$743.50K |
| 2006 | 11.40% | 6.12% | 1.38x | 1.35x | AR$503.20K |
| 2007 | 4.80% | 2.36% | 1.40x | 1.45x | AR$-1.93 Million |
| 2009 | 2.13% | 1.67% | 0.91x | 1.40x | AR$-3.62 Million |
| 2010 | 6.02% | 5.19% | 0.77x | 1.50x | AR$-1.95 Million |
| 2011 | 10.56% | 8.00% | 0.83x | 1.60x | AR$306.90K |
| 2012 | 14.54% | 11.20% | 0.72x | 1.80x | AR$2.90 Million |
| 2014 | 13.04% | 7.75% | 0.76x | 2.20x | AR$1.94 Million |
| 2015 | -1.13% | -0.54% | 0.82x | 2.57x | AR$-7.19 Million |
| 2016 | 13.42% | 6.07% | 0.85x | 2.61x | AR$2.59 Million |
| 2017 | -0.09% | -0.04% | 0.81x | 2.77x | AR$-7.78 Million |
| 2018 | 0.62% | 0.27% | 0.82x | 2.87x | AR$-11.97 Million |
| 2019 | -85.11% | -21.66% | 0.83x | 4.74x | AR$-99.69 Million |
| 2020 | -13.07% | -3.04% | 0.83x | 5.19x | AR$-30.02 Million |
| 2021 | -11.06% | -2.50% | 1.05x | 4.22x | AR$-37.27 Million |
| 2022 | -2.23% | -0.59% | 1.02x | 3.72x | AR$-44.38 Million |
| 2023 | 29.40% | 12.43% | 0.90x | 2.63x | AR$808.98 Million |
| 2024 | -49.86% | -17.13% | 1.10x | 2.65x | AR$-2.24 Billion |
| 2025 | 0.00% | -71.80% | 0.83x | 0.00x | AR$-4.52 Billion |
Industry Comparison
This section compares Instituto Rosenbusch S.A.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,380,505,644
- Average return on equity (ROE) among peers: 14.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Instituto Rosenbusch S.A. (ROSE) | AR$-526.19 Million | 8.43% | N/A | $5.12 Million |
| Laboratorios Richmond SACIF (RICH) | $3.38 Billion | 14.38% | 1.41x | $78.78 Million |
About Instituto Rosenbusch S.A.
Instituto Rosenbusch S.A. manufactures and sells veterinary products in Argentina. The company offers biological products, including products for reproductive-respiratory complex, IBR, BVD, brucelosis, carbuncle, and other diseases; clostridial vaccines; vaccines for cattle, sheep, goats, horses, and dogs; and products for the prevention of pneumonia and calve diarrhea, and cattle infectious kera… Read more